Co-Authors
This is a "connection" page, showing publications co-authored by Guangdi Wang and Madhusoodanan Mottamal.
Connection Strength
2.132
-
Mottamal M, Kang B, Peng X, Wang G. From Pure Antagonists to Pure Degraders of the Estrogen Receptor: Evolving Strategies for the Same Target. ACS Omega. 2021 Apr 13; 6(14):9334-9343.
Score: 0.816
-
Mottamal M, Zheng S, Huang TL, Wang G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules. 2015 Mar 02; 20(3):3898-941.
Score: 0.536
-
Guo S, Zhang C, Mottamal M, Hossain A, Liu J, Wang G. GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models. Breast Cancer Res Treat. 2020 Apr; 180(2):359-368.
Score: 0.188
-
Guo S, Zhang C, Bratton M, Mottamal M, Liu J, Ma P, Zheng S, Zhong Q, Yang L, Wiese TE, Wu Y, Ellis MJ, Matossian M, Burow ME, Miele L, Houtman R, Wang G. ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft models. Oncotarget. 2018 Jan 23; 9(6):6924-6937.
Score: 0.163
-
Zheng S, Zhong Q, Xi Y, Mottamal M, Zhang Q, Schroeder RL, Sridhar J, He L, McFerrin H, Wang G. Modification and biological evaluation of thiazole derivatives as novel inhibitors of metastatic cancer cell migration and invasion. J Med Chem. 2014 Aug 14; 57(15):6653-67.
Score: 0.128
-
Zheng S, Zhong Q, Mottamal M, Zhang Q, Zhang C, Lemelle E, McFerrin H, Wang G. Design, synthesis, and biological evaluation of novel pyridine-bridged analogues of combretastatin-A4 as anticancer agents. J Med Chem. 2014 Apr 24; 57(8):3369-81.
Score: 0.126
-
Zheng S, Zhong Q, Jiang Q, Mottamal M, Zhang Q, Zhu N, Burow ME, Worthylake RA, Wang G. Discovery of a Series of Thiazole Derivatives as Novel Inhibitors of Metastatic Cancer Cell Migration and Invasion. ACS Med Chem Lett. 2013 Feb 14; 4(2):191-196.
Score: 0.116
-
Kang B, Mottamal M, Zhong Q, Bratton M, Zhang C, Guo S, Hossain A, Ma P, Zhang Q, Wang G, Payton-Stewart F. Design, Synthesis, and Evaluation of Niclosamide Analogs as Therapeutic Agents for Enzalutamide-Resistant Prostate Cancer. Pharmaceuticals (Basel). 2023 May 12; 16(5).
Score: 0.059